A “Strong Buy” rating from Wall Street indicates that analysts believe a stock has the potential for future price appreciation. It is typically assigned to stocks that analysts believe are undervalued or have strong growth potential in their respective industries. Let’s look at why Wall Street rates Akebia Therapeutics (AKBA) and Stoke Therapeutics (STOK) as “Strong Buys,” with shares expected to rise by 200% to 300% over the next year.
